TransMedics Group Inc. (TMDX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers.
The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Country | United States |
IPO Date | May 2, 2019 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 584 |
CEO | Dr. Waleed H. Hassanein M.D. |
Contact Details
Address: 200 Minuteman Road Andover, Massachusetts United States | |
Website | https://www.transmedics.com |
Stock Details
Ticker Symbol | TMDX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001756262 |
CUSIP Number | 89377M109 |
ISIN Number | US89377M1099 |
Employer ID | 00-0000000 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Dr. Waleed H. Hassanein M.D. | Founder, President, Chief Executive Officer & Director |
Gerardo Hernandez | Chief Financial Officer |
Anil Ranganath | Senior Vice President, General Counsel & Corporate Secretary |
Dr. Tamer I. Khayal M.D. | Chief Commercial Officer |
Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs |
Nicholas Corcoran | Senior Vice President of Supply Chain & Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 14, 2025 | 8-K | Current Report |
Jan 10, 2025 | 4 | Filing |
Dec 11, 2024 | 4 | Filing |
Dec 09, 2024 | 8-K | Current Report |
Dec 06, 2024 | SCHEDULE 13G/A | [Amend] Filing |
Dec 04, 2024 | 4 | Filing |
Dec 02, 2024 | 3 | Filing |
Dec 02, 2024 | 8-K | Current Report |
Nov 13, 2024 | 4 | Filing |
Nov 07, 2024 | 4 | Filing |